Radioimmunotherapy: Recent results and future directions

Journal of Clinical Oncology

Volumn 14, Issue 4, 1996, Pages 1383-1400

  Wilder, R B ^a   DeNardo, G L ^a   DeNardo, S J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBODY CONJUGATE; ASTATINE 211; BISMUTH; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CHIMERIC ANTIBODY; COPPER 67; CYTOTOXIN; FC RECEPTOR; FERRITIN ANTIBODY; GAMMA INTERFERON; GANGLIOSIDE ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ANTIBODY; LUTETIUM; LYMPHOCYTE ANTIBODY; LYMPHOCYTE ANTIGEN; MONOCLONAL ANTIBODY B.72.3; NERVE CELL ADHESION MOLECULE; RADIOISOTOPE; RECEPTOR ANTIBODY; RHENIUM 188; TENASCIN; TIRAPAZAMINE; TUMOR ANTIGEN; UNINDEXED DRUG; YTTRIUM 90;

ALLERGIC REACTION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG HALF LIFE; DYSPNEA; FEVER; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATUMORAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; NAUSEA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RADIOIMMUNOTHERAPY; RADIOISOTOPE DECAY; RADIOISOTOPE THERAPY; REVIEW; SOLID TUMOR; URTICARIA;

EID: 0029915902     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.4.1383     Document Type: Review

References (209)

1. Eisen HN, Keston AS: The immunologic reactivity of bovine serum albumin labeled with trace-amounts of radioactive iodine (I-131). J Immunol 63:71-80, 1950
2. Pressman D, Korngold L: The in vivo localization of anti-Wagner-osteogenic sarcoma antibodies. Cancer 6:619-623, 1953
3. Pressman D, Day ED, Blau M: The use of paired labeling in the determination of tumor-localizing antibodies. Cancer Res 17:845-850, 1957
4. Beierwaltes WH: Radioiodine-labelled compounds previously or currently used for tumour localization, in Agency IAE (ed): Proceedings of an Advisory Group Meeting on Tumour Localization with Radioactive Agents. Panel Proceedings Series. Vienna, Austria, International Atomic Energy Agency, 1974, pp 47-56
5. Spar IL, Bale WF, Marrack D, et al: 131-I-labeled antibodies to human fibrinogen. Diagnostic studies and therapeutic trials. Cancer 20:865-870, 1967
6. Ettinger DS, Dragon LH, Klein J, et al: Isotopic immunoglobulin in an integrated multimodal treatment program for a primary liver cancer: A case report. Cancer Treat Rep 63:131-134, 1979
7. Ettinger DS, Order SE, Wharam MD, et al: Phase I-II study of isotopic immunoglobulin therapy for primary liver cancer. Cancer Treat Rep 66:289-297, 1982
8. Köhler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497, 1975
9. Esteban JM, Colcher D, Sugarbaker P, et al: Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3. Int J Cancer 39:50-59, 1987
10. Grossbard ML, Press OW, Appelbaum FR, et al: Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80:863-878, 1992
11. Riethmüller G, Schneider GdE, Johnson JP: Monoclonal antibodies in cancer therapy. Curr Opin Immunol 5:732-739, 1993
12. Goldenberg DM: Monoclonal antibodies in cancer detection and therapy. Am J Med 94:297-312, 1993
13. Roninson IB: The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharm 43:95-102, 1992
14. Vitetta ES, Thorpe PE, Uhr JW: Immunotoxins: Magic bullets or misguided missiles? Immunol Today 14:252-259, 1993
15. 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest 72:2101-2114, 1983
16. 2 monoclonal antibody fragments. Radiology 149:549-555, 1983
17. Oettgen HF, Old LJ: The history of cancer immunotherapy, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer. Philadelphia, PA, Lippincott, 1991, pp 87-119
18. Eisenthal A, Shiloni E, Rosenberg SA: Characterization of IL-2-induced murine cells which exhibit ADCC activity. Cell Immunol 115:257-272, 1988
19. Caron PC, Co MS, Bull MK, et al: Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res 52:6761-6767, 1992
20. Takahashi S, Maecker HT, Levy R: DNA fragmentation and cell death mediated by T cell antigen receptor/CD3 complex on a leukemia T cell line. Eur J Immunol 19:1911-1919, 1989
21. Trauth BC, Klas C, Peters AM, et al: Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301-305, 1989
22. Sauvage CA, Mendelsohn JC, Lesley JF, et al: Effects of monoclonal antibodies that block transferrin receptor function on the in vivo growth of a syngeneic murine leukemia. Cancer Res 47:747-753, 1987
23. Cuttitta F, Carney DN, Mulshine J, et al: Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 316:823-826, 1985
24. Masui H, Kawamoto T, Sato JD, et al: Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44:1002-1007, 1984
25. Trowbridge IS, Lopez F: Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro. Proc Natl Acad Sci USA 79:1175-1179, 1982
26. Waldmann TA, Goldman CK, Bongiovanni KF, et al: Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. Blood 72:1805-1816, 1988
27. Fagerberg J, Frodin JE, Ragnhammar P, et al: Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy? Cancer Immunol Immunother 38:149-159, 1994
28. Herlyn D, Wettendorff M, Schmoll E, et al: Anti-idiotype immunization of cancer patients: Modulation of the immune response. Proc Natl Acad Sci USA 84:8055-8059, 1987
29. Mittelman A, Chen ZJ, Kageshita T, et al: Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies [published erratum in J Clin Invest 87:757, 1991]. J Clin Invest 86:2136-2144, 1990
30. Milstein C: Monoclonal antibodies. Sci Am 243:66-74, 1980
31. Dhein J, Daniel PT, Trauth BC, et al: Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol 149:3166-3173, 1992
32. Brezicka FT, Holmgren J, Kalies I, et al: Tumor-cell killing by MAbs against fucosyl GM1, a ganglioside antigen associated with small-cell lung carcinoma. Int J Cancer 49:911-918, 1991
33. Caron PC, Scheinberg DA: Anti-CD33 monoclonal antibody M195 for the therapy of myeloid leukemia. Leuk Lymph 11:1-6, 1993
34. Scholz D, Lubeck M, Loibner H, et al: Biological activity in the human system of isotype variants of oligosaccharide-Y-specific murine monoclonal antibodies. Cancer Immunol Immunother 33:153-157, 1991
35. Keenan AM, Harbert JC, Larson SM: Monoclonal antibodies in nuclear medicine. J Nucl Med 26:531-537, 1985
36. Hazra DK, Britton KE, Lahiri VL, et al: Immunotechnological trends in radioimmunotargeting: From "magic bullet" to "smart bomb." Nucl Med Commun 16:66-75, 1995
37. Zaccolo M, Malavasi F, Hazra DK, et al: From cells to genes: How to make antibodies useful in human diagnosis and therapy. Int J Clin Lab Res 23:192-198, 1993
38. Pennisi E: Mouse of a different YAC. Sci News 143:360-363, 1993
39. Hoffman T: Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. Washington, DC, Food and Drug Administration, 1987
40. Khan FM: The Physics of Radiation Therapy (ed 2). Baltimore, MD, Williams & Wilkins, 1994, pp 22-26, 39, 40, 480
41. Nourigat C, Badger CC, Bernstein ID: Treatment of lymphoma with radiolabeled antibody: Elimination of tumor cells lacking target antigen. J Natl Cancer Inst 82:47-50, 1990
42. Humm JL: Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 27:1490-1497, 1986
43. O'Donoghue JA: The impact of tumor cell proliferation in radioimmunotherapy. Cancer 73:974-980, 1994
44. Wheldon TE, O'Donoghue JA: The radiobiology of targeted radiotherapy. Int J Radiat Biol 58:1-21, 1990
45. 125I]iodobenzoyl conjugate. Bioconjug Chem 2:171-179, 1991
46. 212Pb in radioimmunotherapy. Antib Immunoconjug Radiopharm 5:326, 1992 (abstr 5)
47. 2 fragments with the alpha-particle-emitting nuclide astatine-211: Preservation of immunoreactivity and in vivo localizing capacity. Proc Natl Acad Sci USA 86:7149-7153, 1989
48. Griffiths GL: Radiochemistry of therapeutic radionuclides, in Goldenberg DM (ed): Cancer Therapy With Radiolabeled Antibodies. Boca Raton, FL, CRC, 1995, pp 47-62
49. Durbin PW: Metabolic characteristics within a chemical family. Health Phys 2:225-238, 1960
50. 90Yttrium antiterritin - A new therapeutic radiolabeled antibody. Int J Radiat Oncol Biol Phys 12:277-281, 1986
51. Parker BA, Vassos AB, Halpern SE, et al: Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated antiidiotype monoclonal antibody. Cancer Res 50:1022s-1028s, 1990
52. Vriesendorp HM, Herpst JM, Germack MA, et al: Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01 [published erratum in J Clin Oncol 9:1516, 1991]. J Clin Oncol 9:918-928, 1991
53. Roselli M, Schlom J, Gansow OA, et al: Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies. Int J Radiat Appl Instrum [B] 18:389-394, 1991
54. Shen S, DeNardo GL, DeNardo SJ: Quantitative bremsstrahlung imaging of yttrium-90 using a Wiener filter. Med Phys 21:1409-1417, 1994
55. Shen S, DeNardo GL, Yuan A, et al: Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung. J Nucl Med 35:1381-1389, 1994
56. 67Cu-TETA-Lym-1 antibody in patients with B cell lymphoma. Antib Immunoconjug Radiopharm 4:36, 1991 (abstr 67)
57. DeNardo GL, DeNardo SJ, Meares CF, et al: Pilot therapy of lymphoma with fractionated Cu-67-BAT Lym-1. J Nucl Med 34:93P, 1993 (abstr 370)
58. 67Cu-labeled MAb35 directed against human colonic carcinoma. Antib Immunoconjug Radiopharm 7:76, 1994 (abstr 12)
59. 131I-Lym-1 and mechanisms for improvement, in Epenetos AA (ed): Monoclonal Antibodies 2: Applications in Clinical Oncology. New York, NY, Chapman & Hall, 1993, pp 355-367
60. Eary JF, Krohn KA, Kishore R, et al: Radiochemistry of halogenated antibodies, in Zalutsky MR (ed): Antibodies in Radiodiagnosis and Therapy. Boca Raton, FL, CRC, 1989, pp 83-102
61. Eckelman WC, Paik CH: Labeling antibodies with metals using bifunctional chelates, in Zalutsky MR (ed): Antibodies in Radiodiagnosis and Therapy. Boca Raton, FL, CRC, 1989, pp 103-128
62. Yokoyama K, Reynolds JC, Paik CH, et al: Immunoreactivity affects the biodistribution and tumor targeting of radiolabeled anti-P97 Fab fragment. J Nucl Med 31:202-210, 1990
63. Hnatowich DJ, McGann J: DTPA-coupled proteins-Procedures and precautions. Int J Radiat Appl Instrum [B] 14:563-568, 1987
64. Moi MK, DeNardo SJ, Meares CF: Stable bifunctional chelates of metals used in radiotherapy. Cancer Res 50:789s-793s, 1990
65. Esteban JM, Schlom J, Gansow OA, et al: New method for the chelation of indium-111 to monoclonal antibodies: Biodistribution and imaging of athymic mice bearing human colon carcinoma xenografts. J Nucl Med 28:861-870, 1987
66. Kosmas C, Snook D, Gooden CS, et al: Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy. Cancer Res 52:904-911, 1992
67. Buchsbaum DJ, Wessels BW: Radiolabeled antibody tumor dosimetry, in Goldenberg DM (ed): Cancer Therapy With Radiolabeled Antibodies. Boca Raton, FL, CRC, 1995, pp 21-32
68. Buchsbaum DJ, Wessels BW: Introduction: Radiolabeled antibody tumor dosimetry. Med Phys 20:499-501, 1993
69. Jain RK: Haemodynamic and transport barriers to the treatment of solid tumours. Int J Radiat Biol 60:85-100, 1991
70. Langmuir VK, McGann JK, Buchegger F, et al: The effect of antigen concentration, antibody valency and size, and tumor architecture on antibody binding in multicell spheroids. Int J Rad Appl Instrum [B] 18:753-764, 1991
71. 2, and Fab in tumors. Cancer Res 49:5656-5663, 1989
72. Weinstein JN, Covell DG, Barbet J, et al: Local and cellular factors in the pharmacology of monoclonal antibodies, in Bonavida B. Collier RJ (eds): Membrane Mediated Cytotoxicity. UCLA Symposia on Molecular and Cellular Biology, New Series. New York, NY, Liss, 1987, pp 279-289
73. Griffith MH, Yorke ED, Wessels BW, et al: Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy. J Nucl Med 29:1795-1809, 1988
74. Kwok CS, Prestwich WV, Wilson BC: Calculation of radiation doses for nonuniformity distributed beta and gamma radionuclides in soft tissue. Med Phys 12:405-412, 1985
75. Langmuir VK, Sutherland RM: Dosimetry models for radioimmunotherapy. Med Phys 15:867-873, 1988
76. Humm JL, Cobb LM: Nonuniformity of tumor dose in radioimmunotherapy. J Nucl Med 31:75-83, 1990
77. DeNardo GL, Macey DJ, DeNardo SJ, et al: Quantitative SPECT of uptake of monoclonal antibodies. Semin Nucl Med 19:22-32, 1989
78. Daghighian F, Pentlow KS, Larson SM, et al: Development of a method to measure kinetics of radiolabelled monoclonal antibody in human tumour with applications to microdosimetry: Positron emission tomography studies of iodine-124 labelled 3F8 monoclonal antibody in glioma. Eur J Nucl Med 20:402-409, 1993
79. Scott AM, Macapinlac HA, Divgi CR, et al: Clinical validation of SPECT and CT/MRI image registration in radiolabeled monoclonal antibody studies of colorectal carcinoma. J Nucl Med 35:1976-1984, 1994
80. Sgouros G, Chiu S, Pentlow KS, et al: Three-dimensional dosimetry for radioimmunotherapy treatment planning. J Nucl Med 34:1595-1601, 1993
81. Leichner PK, Koral KF, Jaszczak RJ, et al: An overview of imaging techniques and physical aspects of treatment planning in radioimmunotherapy. Med Phys 20:569-577, 1993
82. Dillehay LE, Williams JR: Radiobiology of dose-rate patterns achievable in radioimmunoglobulin therapy. Front Radiat Ther Oncol 24:96-103, 121-122, 1990
83. Hall EJ: Radiation dose rate: A factor of importance in radiobiology and radiotherapy. Br J Radiol 45:81-97, 1972
84. Fowler JF: Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys 18:1261-1269, 1990
85. Shipley WU, Peacock JH, Steel GG, et al: Continuous irradiation of the Lewis lung carcinoma in vivo at clinically-used "ultra" low-dose-rates. Int J Radiat Oncol Biol Phys 9:1647-1653, 1983
86. Mitchell JB, Bedford JS, Bailey SM: Dose-rate effects on the cell cycle and survival of S3 HeLa and V79 cells. Radiat Res 79:520-536, 1979
87. Mitchell JB, Bedford JS, Bailey SM: Dose-rate effects in mammalian cells in culture III. Comparison of cell killing and cell proliferation during continuous irradiation for six different cell lines. Radiat Res 79:537-551, 1979
88. Szechter A, Schwarz G, Barsa JM: Continuous and fractionated irradiation of mammalian cells in culture - I. The effect of growth rate. Int J Radiat Oncol Biol Phys 4:991-1000, 1978
89. Courtenay VD: Radioresistant mutants of L5178Y cells. Radiat Res 38:186-203, 1969
90. Bedford JS, Mitchell JB, Fox MH: Variations in responses of several mammalian cell lines to low dose-rate irradiation, in Meyn RE, Withers HR (eds): Radiation Biology in Cancer Research. New York, NY, Raven, 1980, pp 251-262
91. Knox SJ, Levy R, Miller RA, et al: Determinants of the antitumor effect of radiolabeled monoclonal antibodies. Cancer Res 50:4935-4940, 1990
92. Neacy WP, Wessels BW, Bradley E, et al: Comparison of radioimmunotherapy (RIT) and 4 MV external beam radiotherapy of human tumor xenografts in athymic mice. J Nucl Med 27:902-903, 1986
93. Wessels BW, Vessella RL, Palme DF II, et al: Radiobiological comparison of external beam irradiation and radioimmunotherapy in renal cell carcinoma xenografts. Int J Radiat Oncol Biol Phys 17:1257-1263, 1989
94. Wessels BW, Neacy WP, York ED: External beam and radiotherapy dosimetry comparison of colorectal xenografts, Proceedings of the Fifth International Radiopharmaceutical Dosimetry Symposium, Oak Ridge, TN, 1991, pp 66-76
95. Knox SJ: Overview of studies on experimental radiotherapy. Cancer Res 55:5832S-5836S, 1995 (suppl 23)
96. Hall EJ: Radiobiology for the Radiologist (ed 4). Philadelphia, PA, Lippincott, 1994
97. 131I-antiferritin tumor localization in experimental hepatoma. Int J Radiat Oncol Biol Phys 10:1135-1141, 1984
98. Dillehay LE, Williams JR: Radiobiological characteristics of radiolabeled immunoglobulin therapy. Proceedings of the 1988 ACNP/SNM Joint Symposium on the Biology of Radionuclide Therapy, Washington, DC, 1989, pp 262-269
99. Knox SJ, Sutherland W, Goris ML: Correlation of tumor sensitivity to low-dose-rate irradiation with G2/M-phase block and other radiobiological parameters [published erratum in Radiat Res 136:439, 1993]. Radiat Res 135:24-31, 1993
100. Sands H, Jones PL, Shah SA, et al: Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts. Cancer Res 48:188-193, 1988
101. Macklis RM, Lin JY, Beresford B, et al: Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: Induction of apoptosis. Radiat Res 130:220-226, 1992
102. Macklis RM, Beresford BA, Palayoor S, et al: Cell cycle alterations, apoptosis, and response to low-dose-rate radioimmunotherapy in lymphoma cells. Int J Radiat Oncol Biol Phys 27:643-650, 1993
103. Cobb LM, Humm JL: Radioimmunotherapy of malignancy using antibody targeted radionuclides. Br J Cancer 54:863-870, 1986
104. 212Bismuth linked to an antipancreatic carcinoma antibody: Model for alpha-particle-emitter radioimmunotherapy. J Natl Cancer Inst 80:449-452, 1988
105. Order SE, Stillwagon GB, Klein JL, et al: Iodine 131 antiferritin, a new treatment modality in hepatoma: A Radiation Therapy Oncology Group study. J Clin Oncol 3:1573-1582, 1985
106. Wessels BW, Rogus RD: Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys 11:638-645, 1984
107. Brown I: Astatine-211: Its possible applications in cancer therapy. Int J Rad Appl Instrum [A] 37:789-798, 1986
108. DeNardo GL, Lewis JP, DeNardo SJ, et al: Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer 73:1425-1432, 1994
109. Cunningham I, Gee TS, Reich LM, et al: Acute promyelocytic leukemia: Treatment results during a decade at Memorial hospital. Blood 73:1116-1122, 1989
110. Jurcic JG, Caron PC, Miller WH, Jr, et al: Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195. Leukemia 9:244-248, 1995
111. Co MS, Avdalovic NM, Caron PC, et al: Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol 148:1149-1154, 1992
112. Waldmann TA: Lymphokine receptors: A target for immunotherapy of lymphomas. Ann Oncol 5:S13-S17, 1994
113. DeNardo SJ, DeNardo GL, O'Grady LF, et al: Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies. Int J Biol Markers 2:49-53, 1987
114. Lewis JP, DeNardo GL, DeNardo SJ: Radioimmunotherapy of lymphoma: A UC Davis experience. Hybridoma 14:115-120, 1995
115. 67Cu-2IT-BAT-Lym-1 and opportunities for improvement, in Goldenberg DM (ed): Cancer Therapy With Radiolabeled Antibodies. Boca Raton, FL, CRC, 1995, pp 217-227
116. Hu E, Epstein AL, Naeve GS, et al: A phase 1a clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies. Hematol Oncol 7:155-166, 1989
117. DeNardo GL, DeNardo SJ, Maddock SW, et al: Efficacy of immunopheresis to reduce myelosuppression in radioimmunotherapy. J Nucl Med 33:863, 1992 (abstr 163)
118. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336-340, 1995
119. Press OW, Eary JF, Appelbaum FR, et al: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219-1224, 1993
120. Press OW, Eary JF, Appelbaum FR, et al: Treatment of relapsed B cell lymphomas with high dose radioimmunotherapy and bone marrow transplantation, in Goldenberg DM (ed): Cancer Therapy With Radiolabeled Antibodies. Boca Raton, FL, CRC, 1995, pp 229-237
121. Knox SJ: Radioimmunotherapy of the non-Hodgkin's lymphomas. Semin Radiat Oncol 5:331-341, 1995
122. 131I]anti-B1 (anti-CD20) antibody. N Engl J Med 329:459-465, 1993
123. 90Y-Anti-CD20 monoclonal antibody therapy for recurrent B cell lymphoma. Int J Radiat Oncol Biol Phys 32:215, 1995 (abstr 148)
124. Juweid M, Sharkey RM, Markowitz A, et al: Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res (in press)
125. Kuzel TM, Winter JN, Rosen ST, et al: Monoclonal antibody therapy of lymphoproliferative disorders. Oncology 4:77-84, 1990
126. Press OW, Eary J, Appelbaum FR, et al: Radiolabeled antibody therapy of lymphoma, in Dana B (ed): Malignant Lymphomas, Including Hodgkin's Disease: Diagnosis, Management, and Special Problems. Boston, MA, Kluwer Academic, 1993, pp 127-145
127. 131I Lym-1 monoclonal antibodies. Int J Cancer 3:96-101, 1988 (suppl)
128. Lybeert ML, Meerwaldt JH, Deneve W: Long-term results of low dose total body irradiation for advanced non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 13:1167-1172, 1987
129. Fuks Z, Kaplan HS: Recurrence rates following radiation therapy of nodular and diffuse malignant lymphomas. Radiology 108:675-684, 1973
130. 131I-Lym-1. Int J Biol Markers 10:67-74, 1995
131. DeNardo SJ, DeNardo GL, O'Grady LF, et al: Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131-LYM-1 monoclonal antibody. Antib Immunoconjug Radiopharm 1:17-33, 1988
132. Rosen ST, Zimmer AM, Goldman-Leikin R, et al: Progress in the treatment of cutaneous T cell lymphomas with radiolabeled monoclonal antibodies. Int J Rad Appl Instrum [B] 16:667-668, 1989
133. Herpst JM, Klein JL, Leichner PK, et al: Survival of patients with resistant Hodgkin's disease after polyclonal yttrium-90 labeled antiferritin treatment. J Clin Oncol 13:2394-2400, 1995
134. DeNardo SJ, Warhoe KA, O'Grady LF, et al: Radioimmunotherapy for breast cancer: Treatment of a patient with I-131 L6 chimeric monoclonal antibody. Int J Biol Markers 6:221-230, 1991
135. DeNardo SJ, Mirick GR, Kroger LA, et al: The biologic window for chimeric L6 radioimmunotherapy. Cancer 73:1023-1032, 1994
136. DeNardo SJ: Radioimmunotherapy in the treatment of metastatic breast cancer: An overview, in Goldenberg DM (ed): Cancer Therapy With Radiolabeled Antibodies. Boca Raton, FL, CRC, 1995, pp 189-202
137. Goodman GE, Hellstrom I, Yelton DE, et al: Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer. Cancer Immunol Immunother 36:267-273, 1993
138. 131I. Comparison of the results obtained in recurrent and newly diagnosed tumours. Cancer Res 55:5952S-5956S, 1995 (suppl 23)
139. Stewart JS, Hird V, Snook D, et al: Intraperitoneal radioimmunotherapy for ovarian cancer: Pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies. Int J Radiat Oncol Biol Phys 16:405-413, 1989
140. Hird V, Maraveyas A, Snook D, et al: Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 68:403-406, 1993
141. Dillman RO, Beauregard JC, Halpern SE, et al: Toxicities and side effects associated with intravenous infusions of murine monoclonal antibodies. J Biol Response Mod 5:73-84, 1986
142. 131I-Lym-1 as a model. Cancer 73:1038-1048, 1994
143. Richman CM, DeNardo SJ, O'Grady LF, et al: Mobilized peripheral blood progenitor cell transfusion permits dose escalation of radiolabeled monoclonal antibody therapy for breast cancer. Breast Cancer Res Treat 2:183, 1992 (abstr 124)
144. 90Y-labeled B72.3 GYK-DTPA immunoconjugate in beagle dogs. Nucl Med Biol 20:571-578, 1993
145. Meredith RF, Khazaeli MB, Liu T, et al: Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med 33:1648-1653, 1992
146. Schlom J, Molinolo A, Simpson JF, et al: Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst 82:763-771, 1990
147. 177lutetium-labeled immunoconjugate. Cancer Res 51:2889-2896, 1991
148. 186Re radioimmunotherapy of small cell lung carcinoma xenografts in nude mice. Cancer Res 51:676-681, 1991
149. 131I-Lym-1 radioimmunotherapy. Antib Immunoconjug Radiopharm 8:227-239, 1995
150. DeNardo SJ, DeNardo GL, Richman CM: Enhancement of clinical radioimmunotherapy for cancer and the role of cytokines. J Natl Cancer Inst 84:374-375, 1992
151. Blumenthal RD, Sharkey RM, Goldenberg DM: Dose escalation of radioantibody in a mouse model with the use of recombinant human interleukin-1 and granulocyte-macrophage colony-stimulating factor intervention to reduce myelosuppression. J Natl Cancer Inst 84:399-407, 1992
152. Bierman PJ, Vose JM, Leichner PK, et al: Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease. J Clin Oncol 11:698-703, 1993
153. Carrasquillo JA, Krohn KA, Beaumier P, et al: Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep 68:317-328, 1984
154. James K: Human monoclonal antibodies and engineered antibodies in the management of cancer. Semin Cancer Biol 1:243-253, 1990
155. Haspel MV, McCabe RP, Pomato N, et al: Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients. Cancer Res 45:3951-3961, 1985
156. Casali P, Inghirami G, Nakamura M, et al: Human monoclonals from antigen-specific selection of B lymphocytes and transformation by EBV. Science 234:476-479, 1986
157. Oi VT, Morrison SL: Chimeric antibodies. Biotechniques 4:214-221, 1986
158. Sun LK, Curtis P, Rakowicz-Szulczynska E, et al: Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A. Proc Natl Acad Sci USA 84:214-218, 1987
159. Shaw DR, Khazaeli MB, LoBuglio AF: Mouse/human chimeric antibodies to a tumor-associated antigen: Biologic activity of the four human IgG subclasses. J Natl Cancer Inst 80:1553-1559, 1988
160. LoBuglio AF, Wheeler RH, Trang J, et al: Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response. Proc Natl Acad Sci USA 86:4220-4224, 1989
161. Meredith RF, LoBuglio AF, Plott WE, et al: Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody. J Nucl Med 32:1162-1168, 1991
162. Jones PT, Dear PH, Foote J, et al: Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321:522-525, 1986
163. Riechmann L, Clark M, Waldmann H, et al: Reshaping human antibodies for therapy. Nature 332:323-327, 1988
164. Weiden PL, Wolf SB, Breitz HB, et al: Human anti-mouse antibody suppression with cyclosporin A. Cancer 73:1093-1097, 1994
165. Ledermann JA, Begent RH, Massof C, et al: A phase-I study of repeated therapy with radiolabelled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin A to suppress the immune response, Int J Cancer 47:659-664, 1991
166. Paganelli G, Pervez S, Siccardi AG, et al: Intraperitoneal radio-localization of tumors pre-targeted by biotinylated monoclonal antibodies. Int J Cancer 45:1184-1189, 1990
167. Weiner LM, Holmes M, Adams GP, et al: A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res 53:94-100, 1993
168. Goodwin DA, Meares CF, McCall MJ, et al: Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med 29:226-234, 1988
169. 111indium BLEDTA-IV clinical imaging in colorectal carcinoma. Antib Immunoconjug Radiopharm 2:1-13, 1989
170. 131I-CC49 and interferon-gamma. Dis Colon Rectum 37:S100-105, 1994
171. 131I-CC49) when given in combination with gamma-interferon. Cancer Res 53:600-608, 1993
172. Guadagni F, Roselli M, Schlom J, et al: In vitro and in vivo regulation of human tumor antigen expression by human recombinant interferons: A review. Int J Biol Markers 9:53-60, 1994
173. Murray JL, Macey DJ, Grant EJ, et al: Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha interferon treatment. Cancer Res 55:5925S-5928S, 1995 (suppl 23)
174. DeNardo GL, DeNardo SJ, Lamborn KR, et al: Enhancement of tumor uptake of monoclonal antibody in nude mice with PEG-IL-2. Antib Immunoconjug Radiopharm 4:859-870, 1991
175. LeBerthon B, Khawli LA, Alauddin M, et al: Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate. Cancer Res 51:2694-2698, 1991
176. Allison MA, Jones SE, McGuffey P: Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors. J Clin Oncol 7:75-80, 1989
177. Msirikale JS, Klein JL, Schroeder J, et al: Radiation enhancement of radiolabelled antibody deposition in tumors. Int J Radiat Oncol Biol Phys 13:1839-1844, 1987
178. Warhoe KA, DeNardo SJ, Wolkov HB, et al: Evidence for external beam irradiation enhancement of radiolabeled monoclonal antibody uptake in breast cancer. Antib Immunoconjug Radiopharm 5:227-235, 1992
179. Stickney DR, Gridley DS, Kirk GA, et al: Enhancement of monoclonal antibody binding to melanoma with single dose radiation or hyperthermia. Monogr Natl Cancer Inst 3:47-52, 1987
180. Shrivastava S, Schlom J, Raubitschek A, et al: Studies concerning the effect of external irradiation on localization of radiolabeled monoclonal antibody B72.3 to human colon carcinoma xenografts. Int J Radiat Oncol Biol Phys 16:721-729, 1989
181. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26:45-50, 1993
182. Okunieff P, Hoeckel M, Dunphy EP, et al: Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone. Int J Radiat Oncol Biol Phys 26:631-636, 1993
183. Bush RS, Jenkin RD, Allt WE, et al: Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 37:302-306, 1978 (suppl)
184. Henk JM, Smith CW: Radiotherapy and hyperbaric oxygen in head and neck cancer. Lancet 2:104-105, 1977
185. Teicher BA, Rose CM: Perfluorochemical emulsions can increase tumor radiosensitivity. Science 223:934-936, 1984
186. Urtasun R, Band P, Chapman JD, et al: Radiation and high-dose metronidazole in supratentorial glioblastomas. N Engl J Med 294:1364-1367, 1976
187. Griffin TW, Pajak TF, Laramore GE, et al: Neutron vs photon irradiation of inoperable salivary gland tumors: Results of an RTOG-MRC Cooperative Randomized Study. Int J Radiat Oncol Biol Phys 15:1085-1090, 1988
188. Krieger JN, Krall JM, Laramore GE, et al: Fast neutron radiotherapy for locally advanced prostate cancer. Update of a past trial and future research directions. Urology 34:1-9, 1989
189. Linstadt DE, Castro JR, Phillips TL: Neon ion radiotherapy: Results of the phase I/II clinical trial. Int J Radiat Oncol Biol Phys 20:761-769, 1991
190. Brown JM, Lemmon MJ: Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int J Radiat Oncol Biol Phys 20:457-461, 1991
191. Zeman EM, Brown JM: Aerobic radiosensitization by SR 4233 in rodent and human cell lines: Mechanistic and therapeutic implications. Int J Radiat Biol 59:117-131, 1991
192. Suter W, Rosselet A, Knusel F: Mode of action of quindoxin and substituted quinoxaline-di-N-oxides on Escherichia coli. Antimicrob Agents Chemother 13:770-783, 1978
193. Brown JM, Lemmon MJ: Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 50:7745-7749, 1990
194. 131I-labeled antibody and the hypoxic cytotoxin SR 4233 in vitro and in vivo [published erratum in Radiat Res 135:130, 1990). Radiat Res 132:351-358, 1992
195. Wilder RB, McGann JK, Sutherland WR, et al: The hypoxic cytotoxin SR 4233 increases the effectiveness of radioimmunotherapy in mice with human non-Hodgkin's lymphoma xenografts. Int J Radiat Oncol Biol Phys 28:119-126, 1994
196. Wilder RB, Langmuir VK, Mendonca HL, et al: Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonie adenocarcinoma xenografts. Cancer Res 53:3022-3027, 1993
197. Leunig M, Goetz AE, Dellian M, et al: Interstitial fluid pressure in solid tumors following hyperthermia: Possible correlation with therapeutic response. Cancer Res 52:487-490, 1992
198. Wong JY, Mivechi NF, Paxton RJ, et al: The effects of hyperthermia on tumor carcinoembryonic antigen expression. Int J Radiat Oncol Biol Phys 17:803-808, 1989
199. 111In-labeled hapten to bifunctional antibody in human colon tumor xenografts. Cancer Res 51:1515-1520, 1991
200. Sneed PK, Phillips TL: Combining hyperthermia and radiation: How beneficial? Oncology 5:99-108, 1991
201. Begent RH, Ledermann JA, Green AJ, et al: Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer. Br J Cancer 60:406-412, 1989
202. Meredith RF, Bueschen AJ, Khazaeli MB, et al: Phase I trial of iodine-131-chimeric B72.3 (human IgG4)in metastatic colorectal cancer. J Nucl Med 33:23-29, 1992
203. 131I-CC49 in colorectal cancer. Cancer 73:1057-1066, 1994
204. 131I antiferritin: An RTOG study. Int J Radiat Oncol Biol Phys 20:953-963, 1991
205. 125I-labeled monoclonal antibody against epidermal growth factor receptor. Antib Immunoconjug Radiopharm 3:169-179, 1990
206. Hopkins K, Chandler C, Bullimore J, et al: A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates. Radiother Oncol 34:121-131, 1995
207. Carrasquillo JA, Krohn KA, Beaumier P, et al: Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep 68:317-328, 1984
208. 131I-3F8 targeted radiotherapy of neuroblastoma (NB): A phase I clinical trial. Proc Am Assoc Cancer Res 31:284, 1990 (abstr 1686)
209. Meredith RF, Bueschen AJ, Khazaeli MB, et al: Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 35:1017-1022, 1994